Spero Therapeutics CMO Debra Zack files initial beneficial ownership statement
SPRO•Initial Section 16 filing
- Spero Therapeutics CMO Debra Jeske Zack filed an initial Section 16 Form 3 on Aug. 6, 2026, covering her holdings in the company.
SPRO•SPRO•
